Fresenius is a Germany-based medical device company that manufactures and supplies in-center and home-care dialysis products for the healthcare industry.
Business Model:
Revenue: $19.7B
Employees: 10,001-999,999
Address: Else-Kroner-Strasse 1
City: Bad Homburg
State: hesse
Zip: 61352
Country: DE
Fresenius is a Germany-based medical device company that manufactures and supplies in-center and home-care dialysis products for the healthcare industry.
Contact Phone:
Contact Email:
Listed Exchange:
Other
IPO Date:
10/18/1996
Ticker Symbol:
FME
Opened: -/share
EBITDA | - |
Total Cash | - |
Total Debt | - |
Total Revenue | - |
Total Profit (Gross) | - |
PE Ratio | - |
Announced Date | Company | Transaction | Money Raised |
---|---|---|---|
7/2019 | BioIntelliSense | Series A | 0 |
3/2014 | ApolloMed | Post-IPO Equity | 12M |
6/2018 | Humacyte | Corporate Round | 150M |
2/2022 | Memo Therapeutics | Series B | 0 |
8/2021 | Humacyte | PIPE | 175M |
11/2017 | Modulim | Series A | 0 |
12/2018 | Tridiuum | Series B | 0 |
11/2019 | EGenesis | Series B | 0 |
1/2019 | Modulim | Series B | 7M |
3/2021 | EGenesis | Series C | 0 |
5/2018 | Vectorious Medical Technologies | Series B | 9M |
7/2018 | Vectorious Medical Technologies | Series B | 2M |
4/2018 | Corvidia | Series B | 60M |
11/2021 | SafeRide Health | Series B | - |
2/2019 | SafeRide Health | Series A | - |
2/2022 | Memo Therapeutics | Series B | 0 |
11/2021 | SafeRide Health | Series B | - |
8/2021 | Humacyte | Post-IPO Equity | 0 |
3/2021 | EGenesis | Series C | 0 |
11/2019 | EGenesis | Series B | 0 |
7/2019 | BioIntelliSense | Series A | 0 |
2/2019 | SafeRide Health | Series A | - |
1/2019 | Modulim | Series B | 0 |
12/2018 | Tridiuum | Series B | 0 |
7/2018 | Vectorious Medical Technologies | Series B | 0 |
Announced Date | Transaction | Number of Investors | Money Raised | Lead Investors | 7/2011 | Post-IPO Equity | $2.7M | 11/2013 | Post-IPO Equity | $26.8M | 8/2017 | Post-IPO Equity | $2.6M | 1/2014 | Post-IPO Equity | $18.2M | 4/2016 | Post-IPO Equity | $39M | 2/2020 | Post-IPO Equity | $6.1M | 1/2015 | Post-IPO Equity | $1.1M | 11/2013 | Post-IPO Equity | $2.6M | 9/2013 | Post-IPO Equity | $2.8M | 5/2013 | Post-IPO Equity | $354.9k | 3/2012 | Post-IPO Equity | $2.3M | 8/2015 | Post-IPO Equity | $5.7M | 2/2016 | Post-IPO Equity | $22.5M | 7/2015 | Post-IPO Equity | $1.1M | 9/2013 | Post-IPO Equity | $4.1M | 7/2013 | Post-IPO Equity | $1.1M | 11/2010 | Post-IPO Equity | $30.2M | 3/2011 | Post-IPO Equity | $653.1k | 4/2018 | Post-IPO Equity | $4.8M | 3/2016 | Post-IPO Equity | $1.2M | 8/2015 | Post-IPO Equity | $2.9M | 7/2015 | Post-IPO Equity | $3.7M |
---|
Announced Date | Name | Price |
---|---|---|
8/2017 | NxStage Medical | |
2/2017 | Cura Group | |
11/2016 | XENiOS | |
9/2016 | Sparsh Nephrocare | |
10/2014 | National Cardiovascular Partners | |
6/2014 | Sound Physicians | |
6/2014 | MedSpring | |
2/2012 | Liberty Dialysis | |
10/2011 | American Access Care | |
8/2011 | Renal Advantage |
|
Revenue: 0 - 100000 Employees: Industry: Software |
Details
|
|
Revenue: 0 - 100000 Employees: 51 - 500 Industry: Education |
Details
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Blockchain |
Details
|
|
Revenue: 0 - 100000 Employees: 11 - 50 Industry: Industrial |
Details
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Advertising |
Details
|